An Outcomes Review of Minimally Invasive Transurethral Convective Water Vapor Energy (WAVE) Therapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

被引:0
|
作者
Shore N.D. [1 ]
机构
[1] Carolina Urologic Research Center, 823 82nd Parkway, Suite B, Myrtle Beach, 29572, SC
关键词
Benign prostatic hyperplasia; Lower urinary tract symptoms; Minimally invasive therapy; Rezūm system; Thermal therapy; Water vapor;
D O I
10.1007/s11884-016-0363-6
中图分类号
学科分类号
摘要
The Rezūm® System utilizing convective water vapor energy (WAVE™) has been proven to safely and effectively ablate obstructive tissue of the prostate, including the median lobe. Clinical trials have demonstrated rapid and significant relief of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) while improving quality of life scores. Moreover, durability of these beneficial results has been demonstrated through 12 months of follow-up. The most common side effects include dysuria, urgency, and hematuria, which are typically of short duration. Importantly, erectile and ejaculatory functions are preserved. This thermal therapy can be performed in an outpatient or office setting under oral sedation, prostate block, or conscious IV sedation. © 2016, Springer Science+Business Media New York.
引用
收藏
页码:153 / 159
页数:6
相关论文
共 50 条
  • [31] First in man study of the ProVee Expander, a novel, minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia
    Anderson, P.
    Lynch, T.
    EUROPEAN UROLOGY, 2023, 83
  • [32] Editorial Comment on "Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study"
    Corona, Giovanni
    JOURNAL OF SEXUAL MEDICINE, 2016, 13 (06): : 934 - 935
  • [33] Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)
    Woo, Henry H.
    Chin, Peter T.
    McNicholas, Thomas A.
    Gill, Harcharan S.
    Plante, Mark K.
    Bruskewitz, Reginald C.
    Roehrborn, Claus G.
    BJU INTERNATIONAL, 2011, 108 (01) : 82 - 88
  • [34] Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
    Franco, Juan V. A.
    Garegnani, Luis
    Escobar Liquitay, Camila Micaela
    Borofsky, Michael
    Dahm, Philipp
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (06):
  • [35] Water Vapor Thermal Therapy: Minimally Invasive Treatment for Benign Prostatic Hyperplasia
    Das, Akhil
    Morgan, Kalon L.
    Yafi, Faysal
    JOURNAL OF ENDOUROLOGY, 2022, 36 : S6 - S11
  • [36] Minimally invasive connective water vapor energy method for benign prostatic hyperplasia
    Cakiroglu, Basri
    UROLOGIA JOURNAL, 2024, 91 (02) : 298 - 305
  • [37] Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia
    Gallegos, Patrick J.
    Frazee, Lawrence A.
    PHARMACOTHERAPY, 2008, 28 (03): : 356 - 365
  • [38] Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system
    De la Cuadra-Grande, Alberto
    Rioja-Zuazu, Jorge
    Dominguez-Esteban, Mario
    Torres, Esperanza
    Blissett, Rob
    Woodward, Emily
    Oyaguez, Itziar
    Fernandez-Arjona, Manuel
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (05) : 499 - 510
  • [39] Transurethral water vapor therapy for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a cost-minimization and budget impact analysis from an Italian healthcare perspective
    Blissett, Robert S.
    Blissett, Deirdre B.
    Oselin, Martina
    Demaire, Clementine
    Woodward, Emily
    Siciliano, Michele
    Torres, Esperanza
    Franzoso, Francesco
    Comelli, Tiziana
    MINERVA UROLOGY AND NEPHROLOGY, 2023, 75 (03): : 343 - 352